Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Ponatinib
Drug ID BADD_D01799
Description Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Indications and Usage Ponatinib is indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.
Marketing Status approved; investigational
ATC Code L01EA05
DrugBank ID DB08901
KEGG ID D09950
MeSH ID C545373
PubChem ID 24826799
TTD Drug ID D0H0EQ
NDC Product Code Not Available
UNII 4340891KFS
Synonyms ponatinib | 3-(2-(imidazo(1,2-b)pyridazin-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-y-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide | ponatinib hydrochloride | AP24534 | AP-24534 | AP 24534 | Iclusig
Chemical Information
Molecular Formula C29H27F3N6O
CAS Registry Number 943319-70-8
SMILES CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cardiomyopathy02.04.01.0010.000224%Not Available
Cardiovascular disorder02.11.01.010; 24.03.02.0090.000526%Not Available
Carotid artery stenosis24.04.06.001; 17.08.02.0010.000168%Not Available
Cataract06.06.01.0010.000224%
Cellulitis23.11.02.004; 11.02.01.001--Not Available
Cerebral infarction24.04.06.002; 17.08.01.0040.000392%Not Available
Cerebrovascular accident24.03.05.001; 17.08.01.0070.001533%
Chest pain22.12.02.003; 08.01.08.002; 02.02.02.0110.001824%Not Available
Chills15.05.03.016; 08.01.09.001--
Cholecystitis09.03.01.0010.000112%
Chromaturia20.02.01.0020.000112%
Chronic myeloid leukaemia16.01.07.001; 01.10.07.0010.002630%Not Available
Circulatory collapse24.06.02.0010.000112%Not Available
Coagulopathy01.01.02.0010.000112%Not Available
Colitis ischaemic24.04.08.012; 07.08.01.0040.000302%Not Available
Constipation07.02.02.0010.001690%
Coronary artery disease02.02.01.001; 24.04.04.0060.000504%Not Available
Coronary artery stenosis12.02.01.037; 24.04.04.017; 02.02.01.0100.000392%Not Available
Cough22.02.03.001--
Deafness04.02.01.0010.000112%Not Available
Death08.04.01.0010.014383%
Decreased activity19.11.01.002; 08.01.01.0060.000112%Not Available
Dehydration14.05.05.0010.000448%
Dermatitis23.03.04.0020.000168%Not Available
Dermatitis acneiform23.02.01.0040.000302%
Dermatitis allergic23.03.04.003; 10.01.03.0140.000168%Not Available
Dermatitis exfoliative10.01.01.004; 23.03.07.0010.000168%
Diabetes mellitus inadequate control14.06.01.004; 05.06.01.0040.000112%Not Available
Diarrhoea07.02.01.001--
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 13 Pages